Life Sciences Archive » January, 2019

Life Sciences - January, 2019

343 articles

• 8 Highlights As Trump Targets Drug-Rebate Kickback Shield
• Panel Leans Toward Valsartan MDL, But Grapples With Scope
• Abilify MDL Plaintiffs Ordered To Defend Their Cases
• How Patent Litigation Changed In 2018
• Delaware Outstrips Texas As Top Patent Hotspot Of 2018
• Patent Injunctions Drop Sharply In 2018
• Despite Drop In AIA Reviews, PTAB Hasn't Lost Its Luster
• J&J Toxicologist Defends Co.'s Talc As 'Clean' At Cancer Trial
• AbbVie, Janssen's $3B Imbruvica Faces First Generic Threat
• Cannabis Cos.' Use Of Foreign Tax Credits May Draw IRS Fire 
• 1st Circ. Revives Fraud Claims In Lexapro, Celexa MDL
• Feds Urge Guilty Verdict For Ex-Pharma CEO In $100M Fraud
• Shareholder Says AbbVie Hid Kickback, Buyback Schemes
• Deals Rumor Mill: Brookfield, Elliott, ConocoPhillips
• DOJ Ends Saline Price-Fixing Probe Against Baxter
• Blood Pressure Med Recalls Cost Us Double, Payers Say
• What Lawyers Can Do To Prevent And Combat Burnout
• The On-Sale Bar After High Court Helsinn Ruling
• J&J's Ethicon Slammed With $41M Verdict In Philly Mesh Case
• Purdue Loses Bid To Keep Mass. Allegations Under Wraps
• Disbarred Atty's Firm Gets $7M In Dow Nuclear Waste Case
• Synergy Execs Get Incentive Pay If Ch. 11 Sale Reaches $214M
• Pharma Fraudsters To Pay Valeant $11.8M Over Kickback Plot
• Pathology Lab Strikes $64M Deal Over DOJ Kickback Claims
• Judge Muffed Ex-Shkreli Atty's Disclosure Duty, Experts Say
• China Proposes Rules For New Tech-Focused Trading Venue
• J&J Pelvic Mesh Patient Endured 'Hell,' Pa. Jury Told
• Key Attys In Boston Scientific Pelvic Mesh MDL To Get $366M
• J&J Pushes Pa. Justices To Limit Risperdal Claims Window
• House Dems Want Insulin Pricing Info From Lilly, Novo, Sanofi
• Boston's Opioid Suit Won't Get Pulled Into Federal Court
• Convicted Doc Tells 2nd Circ. Drug Trial Trades Were Legal
• Antares Faces Records Suit Over Testosterone Drug Troubles
• Invisalign Maker Wasn't Straight About Discounts: Investor
• DOJ Defends Bayer-Monsanto Deal As 'Victory' For Farmers
• The Latest Developments In Antitrust Class Certification
• Dewpoint Therapeutics Lands $60M In Series A Funding
• Approaching Antibody Patents After Amgen V. Sanofi
• 7th Circ. Orders New Trial In Bull Semen-Sorting IP Row
• 9th Circ. Allows Row Over ACA Birth Control Rules To Proceed
• Ex-CEO Tells Chancery Salix Must Pay Her Legal Costs
• USPTO Issues Patent For Cannabis Toothpaste, Mouthwash
• Chinese Engineer Gets 27 Mos. For Trade Secret Theft In US
• HHS Report Card: Attys Grade Health Secretary's 1st Year
• SEC Settles With 4 Cos. Over Alleged Internal Control Failures
• Fresenius Extends $2B Merger Deadline After Shutdown
• Bellwether Trial In Opioid MDL Delayed Another 7 Weeks
• Celgene Says Drug Buyers' Second Try For Cert. No Better
• Opko Shareholder Says CEO's Scandal Sent Stocks To 'Abyss'
• J&J Pushed Risperdal Despite Breast-Growth Risk, Jury Hears
• Fed. Circ. Upholds Rejection Of Blood Sugar Monitor Patent
• Energy Co. Seeks To Speed Up IPO Now That Shutdown Over
• High Court Outlook For False Claims Act Cases In 2019
• Grassley Vows Scrutiny Of Rising Insulin Prices
• Former Alston & Bird Attorney Named Humana GC
• Insuring The Ever-Growing Cannabis Industry: Part 1
• BakerHostetler Atty Accused Of Misusing Info In Opioid MDL
• Chinese Biotech Co. Says Gov't Bias Behind H-1B Visa Denials
• Investor Sues Drugmaker Over Lack Of Control Group In Trials
• Fed. Circ. Medical Device IP Case Highlights ITC Tools
• An Unclear Path For Microbiome-Based Products At FDA
• Cancer Victim's Atty Takes Heat From Judge In Monsanto MDL
• Bitter Backlash Greets Wider Medicare Drug Negotiations
• Punitives Promise Fiercer Fight In Philly Risperdal Trial
• Pharmacy Loses $20M In Its Suit Against Express Scripts
• IPOs Still Face Uncertainty Even As Government Reopens
• J&J May Get Lifeline In Talc Trials From Mo. High Court
• Feds Want FCA Suit Over $21M Kickback Scheme To Proceed
• 'Embarrassing' Purdue Info To Come Out In Mass. Opioid Suit
• Chiesa Shahinian Adds Ex-Pharma Counsel, Prosecutor In NJ
• Mallinckrodt, Express Scripts Must Face Antitrust Suit In Ill.
• German Co. Loses 3 Patents As Suit Against J&J Backfires
• Ex-Insys Execs Driven By Greed To Bribe Doctors, Jury Hears
• Can 'Bundle' Payment Plans Shield Against FCA Liability?
• 15 Minutes With Bristol-Myers Squibb's General Counsel
• 2018 FDA Enforcement Review: Drugs, Biologics And Devices
• Ex-CEO Asks 2nd Circ. For Bail During Valeant Fraud Appeal
• Fed. Circ. Ruling Clears Path For Longer Drug Patent Terms
• The Startup Drugmaker's Post-Helsinn Survival Guide
• More Mass. Claims Against Purdue To Come Out, Judge Says
• Abbott Labs, St. Jude Avoid Suit Over Battery Defects Again
• Device Maker Ev3 Cops To Improper Sales, Pays $18M
• J&J Knew Hip Implants A 'Disaster,' Jury Hears In Retrial
• Indivior Wins Temporary Block On Alvogen Suboxone Generic
• Investors Fight Perrigo's Attempt To Escape Mylan Suit
• Cannabis Cos. Adopting Biotech's Patent Playbook
• Supreme Court Leans Toward Reversal In Merck V. Albrecht
• J&J Didn't Warn Of Talc's Baby Asphyxiation Risks, Jury Told
• Sen. Bill Would Let HHS Prevent Another 'EpiPen Fiasco'
• Split Fed. Circ. OKs $23.5M Medtronic Loss Over Spine IP
• Sanofi Suit Against Mylan To Stay In EpiPen MDL, For Now
• Insys Trial A Salvo In 'Militaristic' Gov't Attack On Opioids
• No Redo On Asacol Class Decertification At 1st Circ.
• Law Schools Should Be More Like Medical Centers
• Deals Rumor Mill: Saudi Aramco, Zambon, Anbang
• Greenberg Traurig Nabs Former 23andMe Privacy Officer
• 7th Circ. Takes Narrow View Of ADEA For Outside Applicants
• FCA Co. Torches DOJ Effort To Scuttle Suits
• Dexcom Defective Device Suit Sent Back To State Court
• Merck Can't Arbitrate Antitrust Suit Over Vaccine Bundles
• Gossamer Bio Seeks $230M IPO Amid Government Shutdown
• Boston Scientific's Del. Merger Trial Still A Go For April
• Fed. Circ. Slams 'Unfair' USPTO Patent Term Adjustment Regs
• Dry Mouth Line Can Stay On Market, Without GSK TMs In Ads
• Deals Rumor Mill: J&J, Union Life, Edcon
• 5 NY Doctors Denounce DOJ Charges Of Insys Kickbacks
• Endo Slams DQ Bid For BakerHostetler Atty In Opioid MDL
• J&J Baby Powder Cover-Up Cost Workers Millions, Suit Says
• Sheppard Mullin Nabs FDA Pro From Sidley Austin
• Pharma Co. Can't Sue FDA Over Rival's Opioid Approval
• Archer Daniels Escapes Bulk Of Deadly Horse Feed Suit
• Scientist Calls Studies Touted By J&J 'Dubious' At Talc Trial
• Walgreens Pays $269M In Milestone FCA Deals
• Valeant Copycat Drug Row Can Stay In Calif., Judge Rules
• Valeant Urges Fed. Circ. To Revive Antifungal Patent
• Direct Buyers Fight GSK, Teva's Bid To Stay Lamictal Suit
• 'On Sale' Ruling Shows Need For Earlier Patent Applications
• Hologic Settles Fujifilm's IP, Antitrust Mammography Suit
• J&J To Pay States $120M For False Hip Implant Promos
• Deals Rumor Mill: Fawaz Alhokair, Saudi Aramco, Colfax
• Consumer Orgs Say NAFTA 2.0 Will Keep Drug Prices High
• Courts Are Getting It Right On Litigation Funding Discovery
• 8 Promo Pitfalls Pharma Compliance Chiefs Need To Know
• FDA Releases Guidance On Clearing New Medical Devices
• Fed. Circ. Urged Not To Review Venue In $20M Cialis IP Row
• International Law In 2018: Key Developments
• High Court Says AIA Did Not Change Meaning Of On-Sale Bar
• EU Eyeing Opening Markets For Biosimilar, Generic Drugs
• Drug Distributors Can't Appeal RICO Ruling In Opioid MDL
• UnitedHealth Sues Generic-Drug Makers For Price-Fixing
• Pharma Investor Says $180M Deal Proxy Lacks Key Info
• PTAB Denies Novartis' Challenge To Cancer Drug Patents
• Pa. Judge Urged To Make J&J CEO Testify In Risperdal Trial
• Theranos Execs' Days Of Reckoning Draw Nearer
• Life Sciences Group Of The Year: White & Case
• Health Hires: Norton Rose, K&L Gates, Fox Rothschild
• The US Biosimilars Patent Litigation Outlook For 2019
• Settlement Counsel Key For Efficient Mass Tort Resolution
• Imerys Must Face Suit Alleging Talc Caused Woman's Cancer
• Medical Device Co.'s Del. Suit Says Competitor 'Sabotaged' It
• Spectrum Adds Shutdown To Deal Clock, Others Could Follow
• NYC Adds Sacklers, Drugstore Chains To Opioid Suit
• Lens.com Can't Ditch Or Move Alcon TM Suit, NY Judge Says
• Fla. Gov. Wants Legislature To Cut Medical Pot Smoking Ban
• Revance Prices $100M Preapproved Offering Amid Shutdown
• Hunger For New Drugs, Tech To Drive 2019 Pharma M&A
• Insulin Patients Impacted By Drug-Pricing Scheme, Court Told
• Chancery's Toss Of $3M Biotech Co. Breach Claim Stands
• PTAB Axes Fish Oil Patent In Post-Grant Review
• Stevens & Lee Nabs Ballard Partner For Tech Co-Chair Role
• Diversity's Next Step: Developing Minority Partners
• Takeaways From Fed. Circ. Hatch-Waxman IPR Case
• Alzheimer's Drug Co. Alzheon Again Nixes IPO Plans
• What Cannabis Patent Applicants Can Learn From Biopharma
• 2019 Annual Meeting And Reporting Considerations: Part 4
• Life Sciences Group Of The Year: Weil
• NJ Atty Seeks Revival Of Homeopathic Flu Remedy Fraud Suit
• Religious Bias Suit OK'd Over Pfizer's Iffy Arbitration Policy
• Curious Jury Gets Answers From Pathologist In J&J Talc Trial
• Mo. High Court Hits Pause On Looming J&J Talc Cancer Trial
• Outcome Health Adds Compliance Chief After Fraud Claims
• PetIQ Chews On Rivals' Fresh Suit Over Clinic Chain Buy
• Drugmakers Aim To Bump Delinquent Plaintiffs In Abilify MDL
• Hernia Mesh Maker Can't Revive IP Suit Coverage Bid
• J&J Renews Bid To End Antitrust Suit From Walgreens, Kroger
• Opioid Distributors Want 6th Circ. RICO Ruling Before Trial
• Insys Shareholders Want Stay Lifted In Fentanyl Chancery Suit
• Ariad Exec's Ex Gets 18 Months For Trading On Drug Info
• Opioid User Testimony To Be Key Factor In Mass. Insys Trial
• NY AG Wants Pharma Co.'s DOJ Settlement Docs
• Sichenzia Ross Steers Calif. Biopharma Firm On $20M IPO
• 2019 Annual Meeting And Reporting Considerations: Part 3
• 2018 Trends In HHS Corporate Integrity Agreements
• UK Patent Law: Hot Topics Of 2018 And What's Ahead
• Life Sciences Group Of The Year: Paul Weiss
• Arbitrators And Mediators Should Reflect Society's Diversity
• Purdue Brass Pinned Opioid Crisis On Addicts, Mass. AG Says
• Greatbatch Gets $22M In Redo Of Pacemaker Patent Trial
• Insurer Wants Out Of Covering Depomed In Opioid Litigation
• Gottlieb Says 400 FDA Staff Back On Inspections
• Chancery Trims Fee Award In Miramar Class Merger Challenge
• 2 Companies Join IPO Pipeline With Filings Totaling $47M
• Why AFAs Are Key To The Future Of Legal Practice
• Akorn Wants Derivative Suit Related To Failed Merger Axed
• Barr Walks Back Anti-False Claims Act Whistleblower Views
• Lewis Brisbois Lands Segal McCambridge Team In Philly
• What Conn. Opioid Ruling Means For Liability Insurers
• Life Sciences Group Of The Year: Latham & Watkins
• 2019 Annual Meeting And Reporting Considerations: Part 2
• Edwards Pays Boston Scientific $180M, Ending All IP Fights
• How A No-Deal Brexit Would Affect Life Sciences Cos.
• Skip Md.'s Bid To Revive Price-Gouging Law, Justices Urged
• Robitussin Buyer Seeks Cert. In Label Suit Against Pfizer
• Allergan's Attack On Drug Compounding Falls Flat
• Fed. Circ. Affirms Generics Win In Colitis Patent Suit
• Baker Botts Defeats Takeda's DQ Bid In Heartburn Drug Fight
• Biologist Found J&J Talc In Dying Woman's Tissue, Jury Hears
• J&J Faces Retrial After $151M Hip Implant Loss Reversed
• Mylan Fights To Put Consumer On Stand In Celgene Clash
• Teva Tries To Nix Investors' 'Defective' Price-Hike Suit
• House Oversight Launches Probe Over Top-Dollar Drugs
• 2 Biotech Firms, Chinese Lender File IPOs Totaling $192M
• Allergan, St. Regis Urge Justices To OK PTAB Tribal Immunity
• 2019 Annual Meeting And Reporting Considerations: Part 1
• Circuits Left To Develop FCA Discovery Case Law
• Ethicon Gets One Covidien Claim Tossed In Patent Dispute
• Med Tech Co.'s Jurisdiction Appeal Is Improper, Judge Says
• Ex-GC Returns To Lead Haynes And Boone Group In Dallas
• Pharmacy, PE Fund Back Judge's Trim Of $70M FCA Suit
• Exhibit List Ordered Trimmed After Insys Execs Blast Gov't
• The Trump Administration's Latest Drug Pricing Initiatives
• Judging A Book: Barron Reviews 'The Clamor Of Lawyers'
• Doc Who Shared Teen Patient Info With Drug Co. Avoids Jail
• Pharma. Co. Egalet's Ch. 11 Confirmed In Delaware
• Cannabis S Corps Should Reconsider Restructuring
• Life Sciences Group Of The Year: King & Spalding
• Handling Corporate Congressional Probes In The Trump Era
• The Firms That Dominated In 2018
• Law360 Names Practice Groups Of The Year
• Uncertain Deals Climate Persists After JPMorgan Conference
• DLA Piper Decries DQ From $45M Blue Cross Payment Fight
• DOJ's Slumping FCA Hauls Cloud Future Recovery Prospects
• Fed. Circ. OKs PTAB Save Of Patent Covering Pfizer's Toviaz
• 3 Takeaways From The PTAB's Cannabis Experience
• Chancery Decision In CytRx Attys' Fees Dispute Upheld
• Health Hires: Lewis Brisbois, Pierce Bainbridge, Bradley Arant
• FTC Must Appear In AndroGel Case Despite Shutdown
• The Case For Lawyer-Directed Litigation Funding In NY: Part 2
• 9th Circ. Tosses Suit Over 'Useless' Vitamin E Supplements
• Teva Inks $135M Settlement In Ill. Medicaid Fraud Case
• What All Attorneys Need To Know About The Shutdown
• J&J Knew Of Baby Powder's Link To Cancer In '71, Jury Told
• CytoDyn, Investors End Chancery Director Options Suit
• Patent Ineligibility Revamp Shouldn't Up Rejections: USPTO
• FDA Won't Add Black Box Warning To Blood Thinner Plavix
• '60 Minutes' Ethics Feud Ends In Opioid MDL
• House Dems Pass Spending Bills, But Impasse Far From Over
• Ex-Insys Sales Rep Loses Bid To Split From Upcoming Trial
• Biotech CEO Rips Prosecutors, Gets 27 Mos. For Fraud, Lies
• Pa. Judge Won't Toss Mesh Trial After Three-Week Delay
• 5th Circ. Affirms Ex-ArthroCare CEO's 20-Year Fraud Sentence
• The Case For Lawyer-Directed Litigation Funding In NY: Part 1
• Patenting Cannabis: A Look At The Numbers
• 2nd Circ. Upholds Ex-Hunton Atty's Insider Trading Conviction
• BakerHostetler Atty Faces Disqualification Bid In Opioid MDL
• Plaintiffs Attys Rip 'Dishonest' Ethics Complaint In Opioid MDL
• Ex-Pharma CEO's $100M Bank Fraud Trial Opens
• Biotech Co. Asks Del. Justices To Reverse $3M Breach Ruling
• Conn. Judge Tosses Cities' Suits Against Opioid Makers
• Full Fed. Circ. Rejects Vaccine Act Case, Overruling 2 Judges
• Biometrics Co. Dodges Claims It Bribed Foreign Execs
• Ex-Insys CEO Pleads Guilty, May Testify In Bribery Trial
• Insys Founder Need Not Comply With Subpoena, Judge Rules
• Patent Eligibility Lessons From PTAB's Use Of Berkheimer
• Accounting Treatment Pitfalls To Avoid In Life Sciences M&A
• RI Law May Force Atty To Face Malpractice Suit, Judges Say
• Health Care Fraud Enforcement In 2018, And 2019 Predictions
• 7 Questions To Add To Your Lateral Partner Questionnaire
• 'Botched' Merger Disclosures Put Ambry On Hook For $450K
• Ex-Novartis Exec Fired Over Study Objections, NJ Jury Told
• Full Fed. Circ. Urged To Review 'Unclear' Double-Patent Rules
• GSK, Laid-Off Workers Fight Over Denial Of Severance
• $3.3M Deal Over Unwanted Ad Faxes Receives Early OK
• Fla. Urges Appeals Court To Keep Medical Pot Smoking Ban
• FDA Focus: What Venable's Practice Chair Is Watching
• Farm Bill Brings IP Options For Breeders Of New Plants
• A Chat With Reed Smith Chief Marketing Officer Sadie Baron
• FDA Understood Proposed Fosamax Warnings, Justices Told
• J&J Baby Powder Caused Dying Woman's Cancer, Jury Told
• High Court Roundup: Justices Refuse To Hear 5 Patent Cases
• Tesaro Hit With Investor Suit Over $5B Merger Deal With GSK
• Justices Pass On Appeal Of Sanctions For Presuit Actions
• Cooley Guides Cancer-Focused Biotech's $115M IPO Filing
• Gov't Says Chicago Can't Object To $625M FCA Deal
• High Court Won't Take Up Depakote Birth Defect Suit
• Preemption In Pharmaceutical Cases: 2018 In Review
• High Court Denies Gilead FCA Case After DOJ Thumbs-Down
• Weil, Fenwick Steer Eli Lilly's $8B Loxo Oncology Buy
• 'Flexible Work' Makes Freelancing More Viable In BigLaw
• A Call To Permit Judicial Substitution In MDL Proceedings
• Judge Weinstein On Activism, Gobbledegook, Going Robeless
• Johns Hopkins, Others Lose Bid To Kill Syphilis Study Suit
• Up Next At High Court: Drugs, Copyrights And State Immunity
• USPTO Patent Eligibility Revamp Expected To Cut Rejections
• Drug Cos. Decry 'Flagrant' Ethical Lapses In Opioid Cases
• Synergy Pharma Negotiates, Locks In Ch. 11 Sale Procedures
• Medical Device Co. Gets Nod For Ch. 11 Financing
• Full Fed. Circ. Won't Revisit 'Blocking Patent' Ruling
• Brand Battles: Johnson & Johnson, Monster, Amazon
• Judge Won't Gag AGs In Generics Price-Fixing Case
• Attys Head To JPMorgan Conference In Shaky Deals Climate
• Drugmaker Perrigo Hit With Investor Suit Over Tax Audit
• Abiomed Escapes $2.1M Equity Suit Brought By Fired Exec
• Genomic Sequencing Cos. Face FTC Scrutiny On $1B Deal
• Taxation With Representation: Wachtell, Simpson, MoFo
• Eyes On FTC After Canada's Drug Sampling Probe Flops
• Health Hires: Locke Lord, Morgan Lewis, Amneal, Novant
• Esperion Inks Daiichi Licensing Deal For Cholesterol Drugs
• KKR Affiliate Loans Food Allergy-Focused Biopharma $170M
• Teva, GSK Want Lamictal Suit Paused To Appeal Class Cert.
• A Closer Look At New Pharmaceutical Hazardous Waste Regs
• Allergan, St. Regis Drop 2 Short-Lived Restasis IP Suits
• Mylan Gets 2030 Linzess Launch After Allergan Deal
• GYNs Get Third Try At Cynosure 'Vaginal Rejuvenation' Suit
• Bristol-Myers' $74B Celgene Buy Gives 2019 M&A Fast Start
• Hypertension Therapy Co. Closes $77M Funding Round
• FisherBroyles Snags Health Industry Counsel As Partner
• Ag Co. Can't Duck Decision Calling Products 'Pesticides'
• What To Expect From Technology-Assisted Review In 2019
• AGs Blast Generic Cos.' Bid To Gag Price-Fixing Comments
• Clinical Trials: 2018 Litigation And Guidance Roundup
• Monsanto Roundup Buyers Denied Cert. In Wis.
• Kirkland, Wachtell Steer Bristol-Myers' $74B Celgene Buy
• Health Care Drove Most Of $2.9B In 2018 FCA Recoveries
• Firestorm Engulfs Trump's 'Int'l Pricing Index' For Drugs
• Allergy Co.'s Antitrust Suit Recycles Failed Trial, BCBS Says
• Synergy Pharma Defends Ch. 11 Sale Plan After Objections
• Orrick Nabs 2nd Fenwick & West Tech IPO Pro
• NJ Medical Device Co. Seeks Financing In Del. Ch. 11
• Full Fed. Circ. Won't Touch MS Drug Patent Royalties Fight
• USPTO Takes Win-Or-Lose Atty Fee Rule To Supreme Court
• Justices Told Fed. Circ. Ruling Made Mayo A 'Dead Letter'
• 4 Post-Christmas IPO Filings Perk Up January Pipeline
• 2nd Bellwether Track Set In Opioid MDL
• 2019 Will Bring More Good News For Litigation Finance
• Top 5 Drug And Medical Device Developments Of 2018
• Manufacturers Face The Rise Of Global Class Actions
• Atlas Venture Lands $250M In Latest Fund
• Former Insys CEO Will Plead Guilty In Opioid Kickback Case
• The Hottest Patent Law Issues Of 2018
• Why More Law Firms Will Embrace Remote Work In 2019
• Native American Cases To Watch In 2019
• Trials To Watch In 2019
• Health Care Cases To Watch In 2019
• California Cases To Watch In 2019
• Patent Cases To Watch In 2019
• Life Sciences Cases To Watch In 2019
• Pennsylvania Cases To Watch In 2019
• Supreme Court Class Action Cases To Watch In 2019
• Massachusetts Trends And Cases To Watch In 2019
• New Jersey Cases To Watch In 2019
• Product Liability Regulation & Legislation To Watch In 2019
• Product Liability Cases To Watch In 2019